UY31448A1 - Compuestos de 1,2,4,-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3. - Google Patents

Compuestos de 1,2,4,-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3.

Info

Publication number
UY31448A1
UY31448A1 UY31448A UY31448A UY31448A1 UY 31448 A1 UY31448 A1 UY 31448A1 UY 31448 A UY31448 A UY 31448A UY 31448 A UY31448 A UY 31448A UY 31448 A1 UY31448 A1 UY 31448A1
Authority
UY
Uruguay
Prior art keywords
dopamine
compounds
respond
disorders
diona
Prior art date
Application number
UY31448A
Other languages
English (en)
Inventor
Anton Bespalov
Ana Jongen-Relo
Liliane Unger
Karla Drescher
Udo Lange
Sean Colm Turner
Andreas Haupt
Wilfried Martin Braje
Herve Geneste
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31448(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31448A1 publication Critical patent/UY31448A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de formula I: en donde A, R1, R2; R3 y R4 son como se definen en la memoria y reivindicaciones y las sales de estos compuestos y sus N-oxidos. Composicion farmacéutica que comprende al menos un compuesto de la formula I y/o al menos una sal de adicion ácida del mismo, y con un método para tratar trastornos que responden beneficiosamente a antagonistas del receptor de dopamina D3 o agonistas de dopamina D3, donde dicho método comprende administrar una cantidad eficaz de al menos un compuesto o una sal de adicion ácida de la formula I a un sujeto que lo necesita.
UY31448A 2007-11-02 2008-10-31 Compuestos de 1,2,4,-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3. UY31448A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07119927 2007-11-02

Publications (1)

Publication Number Publication Date
UY31448A1 true UY31448A1 (es) 2009-05-29

Family

ID=40210491

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31448A UY31448A1 (es) 2007-11-02 2008-10-31 Compuestos de 1,2,4,-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3.

Country Status (29)

Country Link
US (1) US8492540B2 (es)
EP (1) EP2217593B1 (es)
JP (1) JP5559694B2 (es)
KR (1) KR20100094491A (es)
CN (1) CN101932574B (es)
AR (1) AR069150A1 (es)
AT (1) ATE556069T1 (es)
AU (1) AU2008320814B2 (es)
BR (1) BRPI0818726A2 (es)
CA (1) CA2704533C (es)
CL (1) CL2008003253A1 (es)
CO (1) CO6280473A2 (es)
CR (1) CR11410A (es)
DO (1) DOP2010000126A (es)
EC (1) ECSP10010227A (es)
ES (1) ES2386691T3 (es)
HK (1) HK1146628A1 (es)
IL (1) IL205468A0 (es)
MX (1) MX2010004830A (es)
MY (1) MY154066A (es)
NZ (1) NZ585051A (es)
PA (1) PA8802101A1 (es)
PE (1) PE20090950A1 (es)
RU (1) RU2478633C2 (es)
TW (1) TWI463984B (es)
UA (1) UA99634C2 (es)
UY (1) UY31448A1 (es)
WO (1) WO2009056625A1 (es)
ZA (1) ZA201003593B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9505753B2 (en) 2012-08-08 2016-11-29 The Johns Hopkins University Inhibitors of D-amino acid oxidase
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
AR095264A1 (es) 2013-03-15 2015-09-30 Abbvie Deutschland Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
UY35420A (es) 2013-03-15 2014-10-31 Abbvie Inc Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
KR102643833B1 (ko) 2022-06-30 2024-03-06 현대제철 주식회사 이강종 연연주시 강종 예측 정합성 증대 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
DE4425143A1 (de) 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
FR2727682A1 (fr) 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
FR2769913B1 (fr) * 1997-10-16 2000-03-10 Pf Medicament Nouveaux derives cyclohexaniques difonctionnalises en 1, 4, leur preparation et leur application therapeutique humaine
DE10311065A1 (de) 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
JP2004359689A (ja) * 2003-06-05 2004-12-24 Abbott Gmbh & Co Kg ドーパミンｄ３受容体のモジュレーションに反応する障害の治療に適するトリアゾール化合物
DE102004027359A1 (de) * 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
US8202868B2 (en) * 2004-08-09 2012-06-19 Abbott Gmbh & Co. Kg 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
KR20070106989A (ko) * 2004-12-02 2007-11-06 애보트 게엠베하 운트 콤파니 카게 도파민 ｄ₃ 수용체의 조정에 반응하는 장애의 치료에적합한 트리아졸 화합물
DE102004061593A1 (de) * 2004-12-21 2006-06-22 Abbott Gmbh & Co. Kg Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung
CN101796033A (zh) * 2007-06-28 2010-08-04 英特维特国际股份有限公司 作为cb1拮抗剂的取代的哌嗪

Also Published As

Publication number Publication date
PE20090950A1 (es) 2009-08-08
PA8802101A1 (es) 2009-08-26
MY154066A (en) 2015-04-30
CA2704533C (en) 2016-09-06
UA99634C2 (ru) 2012-09-10
CA2704533A1 (en) 2009-05-07
CN101932574A (zh) 2010-12-29
CL2008003253A1 (es) 2009-11-13
NZ585051A (en) 2012-03-30
WO2009056625A1 (en) 2009-05-07
HK1146628A1 (en) 2011-06-24
CO6280473A2 (es) 2011-05-20
CR11410A (es) 2010-09-13
RU2010122337A (ru) 2011-12-10
AR069150A1 (es) 2009-12-30
US20100311755A1 (en) 2010-12-09
AU2008320814A1 (en) 2009-05-07
US8492540B2 (en) 2013-07-23
EP2217593A1 (en) 2010-08-18
TW200927132A (en) 2009-07-01
ES2386691T3 (es) 2012-08-27
MX2010004830A (es) 2010-10-20
ZA201003593B (en) 2011-02-23
JP5559694B2 (ja) 2014-07-23
RU2478633C2 (ru) 2013-04-10
ATE556069T1 (de) 2012-05-15
TWI463984B (zh) 2014-12-11
BRPI0818726A2 (pt) 2015-04-22
KR20100094491A (ko) 2010-08-26
JP2011502971A (ja) 2011-01-27
DOP2010000126A (es) 2010-06-15
EP2217593B1 (en) 2012-05-02
ECSP10010227A (es) 2010-08-31
AU2008320814B2 (en) 2013-07-11
CN101932574B (zh) 2014-07-23
IL205468A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
CO6300941A2 (es) Compuestos de quinuclidina como ligandos del receptor nicotinico de acetilcolina alfa 7
CR10948A (es) Compuestos triciclicos, composiciones y procedimientos
NI201100052A (es) Derivados de picolinamida como inhibidores de cinasa.
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
UY32045A (es) Compuesto amida
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
EA201300869A1 (ru) Морфинановые соединения
EA201001331A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-kit И PDGFR
CR20120177A (es) Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes
CO6321136A2 (es) Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p)
SV2011003855A (es) Heteroarilos sustituidos
GT200800158A (es) Pirazolquinolonas como potentes inhibidores de parp
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
UY31448A1 (es) Compuestos de 1,2,4,-triazin-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de dopamina d3.
PE20160842A1 (es) Piperidiniltetrahidroquinolinas sustituidas
UY33722A (es) Oxazolidinonas como moduladores de mglur5
PE20170770A1 (es) Metodos y composiciones para tratar trastornos relacionados con vih
ECSP088761A (es) Nuevas combinaciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos
CY1117565T1 (el) Συνενωμενο δικυκλικο παραγωγο 2,4-διαμινοπυριδινης ως διπλος αναστολεας alk και fak
BR112014011262A2 (pt) carboxamida com base em pirazolila substituída e derivados de ureia que portam uma porção de fenila substituída com um grupo contendo o como ligantes de receptor vaniloide

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171017